Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1673-1683

  Lobo, Merryl R ^a   Green, Sarah C ^b   Schabel, Matthias C ^d   Gillespie, G Yancey ^c   Woltjer, Randall L ^b   Pike, Martin M ^a  

^a Advanced Imaging Research Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Autophagy; Cediranib; Glioma; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; CEDIRANIB; MEPACRINE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER GROWTH; CELL VACUOLE; CONTROLLED STUDY; DEVASCULARIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GLIOMA; IMMUNOHISTOLOGY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR NECROSIS; TUMOR VOLUME; WESTERN BLOTTING;

ANTIANGIOGENESIS; AUTOPHAGY; CEDIRANIB; GLIOMA; MRI;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; DRUG SYNERGISM; FEMALE; GLIOMA; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; QUINACRINE; QUINAZOLINES; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84891873001     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not119     Document Type: Article

References (49)

1. Gladson CL, Prayson RA, Liu WM. The pathobiology of glioma tumors. Annu Rev Pathol. 2010;5:33-50
2. Norden AD, Drappatz J,Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009;5(11):610-620
3. Rahman R, Smith S, Rahman C, Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol. 2010;2010:251231
4. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: Afamiliar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65(6): 529-539.
5. Tabatabai G, Stupp R. Primetime for antiangiogenic therapy. Curr Opin Neurol. 2009;22(6):639-644
6. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603
7. Gotink KJ,VerheulHM.Anti-angiogenic tyrosine kinase inhibitors: whatis their mechanism of action? Angiogenesis. 2010;13(1):1-14
8. HuYL, DeLayM,Jahangiri A, et al.Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72(7):1773-1783
9. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2005;7(2):134-153
10. Rouschop KM, Wouters BG. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr Mol Med. 2009;9(4): 417-424
11. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8(11): 851-864
12. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010;6(3):322-329
13. GeP, LuoY, Fu S, Ji X, Ling F. Autophagy: A strategy for malignant gliomas' resistance to therapy. Med Hypotheses. 2009;73(1):45-47
14. Hoyer-Hansen M, Jaattela M. Autophagy: An emerging target for cancer therapy. Autophagy. 2008;4(5):574-580
15. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer developmentandresponsetotherapy.NatRev Cancer.2005;5(9):726-734
16. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol. 2010;12(5):473-481
17. Kaza N, Kohli L, Roth KA. Autophagy in brain tumors: A new target for therapeutic intervention. Brain Pathol. 2012;22(1):89-98
18. Amaravadi R. Autophagy can contribute to cell death when combining targeted therapy. Cancer Biol Ther. 2009;8(21):130-133
19. Degtyarev M, De Maziere A, Orr C, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol. 2008;183(1):101-116
20. Mirzoeva OK, Hann B, Hom YK, et al. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011;89(9):877-889
21. Shimizu S, Takehara T, Hikita H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2011;131(3):548-557
22. Marceau F, Bawolak MT, Bouthillier J, Morissette G. Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: A model for the distribution of lipophilic cationic drugs to autophagic vacuoles. Drug Metab Dispos. 2009;37(12):2271-2274
23. Gupta A, Roy S, Lazar AJ, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A. 2010;107(32):14333-14338
24. Yung L, Huang Y, Lessard P, et al. Guglielmo BJ, Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis. 2004;4:53
25. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: A novel means to combat apoptosis-resistant cancers, with a specialemphasis on glioblastomas. Oncologist. 2007;12(12):1395-1403
26. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10): 4389-4400
27. Lobo MRHE, Kurre P, Schabel MC, Gillespie GY, Pike MM. Autophagy inhibitor quinacrine synergistically enhances anti-angiogenic efficacy of cediranib in intracranial mouse glioma [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR. Cancer Research. 2012; 72(8 Suppl)
28. Dyer CA, Philibotte T. A clone of theMOCH-1 glial tumor in culture: multiple phenotypes expressed under different environmental conditions. J Neuropathol Exp Neurol. 1995;54(6):852-863
29. Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, Gillespie GY. High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med. 2009;61(3):615-625
30. Zhang X, Samadi AK, Roby KF, Timmermann B, Cohen MS. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol. 2011;124(3):606-612
31. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223-232
32. Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol. 2012;57(2):R1-R33
33. Schabel MC, Parker DL. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol. 2008;53(9):2345-2373
34. Schabel MC, DiBella EV, Jensen RL, Salzman KL. A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II. In vivo results. Phys Med Biol. 2010;55(16):4807-4823
35. Schabel MC, Fluckiger JU, DiBella EV. A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrastenhanced MRI: I.: simulations. Phys Med Biol. 2010;55(16):4783-4806
36. OstergaardL,Weisskoff R, Chesler D, Gyldensted C. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. MRM. 1996;36:715-725
37. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging. 2007;26(2):235-249
38. Koumenis C,Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res. 2006;4(7):423-436
39. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40(2):280-293
40. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486
41. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27(15):2542-2552
42. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-563
43. Bradley DP, Tessier JJ, Lacey T, et al. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: A dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging. 2009;27(3):377-384
44. Farrar CT, Kamoun WS, Ley CD, et al. Sensitivity ofMRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS One. 2011;6(3):e17228
45. Farrar CT, Kamoun WS, Ley CD, et al. Sensitivity ofMRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS One. 2011;6(3):e17228
46. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95
47. SorensenAG,Emblem KE, PolaskovaP, et al. Increased survival of glioblastoma patientswhorespond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72(2):402-407
48. Takeuchi H, Kanzawa T, Kondo Y, Kondo S. Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells. Br J Cancer. 2004;90(5):1069-1075
49. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, et al. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res. 2007;13(15 Pt 1):4519-4527